Archives

2025

Transcriptomics Market Size, Share and Trends Forecast 2025-2033

Market Overview:

The Transcriptomics Market is experiencing steady expansion, driven by Ongoing Advancements in Next-Generation Sequencing (NGS) Technologies, Rising Demand for Personalized Medicine and Increasing Investments in Genomic Research by Government and Private Entities. According to IMARC Group's latest research publication, "Transcriptomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025–2033", The global transcriptomics market size was valued at USD 7.6 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 12.1 Billion by 2033, exhibiting a CAGR of 5.3% from 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/Transcriptomics-Market/requestsample

Our Report Includes:

• Market Dynamics
• Market Trends and Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Transcriptomics Industry:

• Ongoing Advancements in Next-Generation Sequencing (NGS) Technologies

The rapid evolution of Next-Generation Sequencing (NGS) technologies is the foundational driver for the expanding transcriptomics market. These advancements have drastically improved the accuracy, speed, and cost-efficiency of sequencing RNA, allowing for ultra-high throughput analysis of gene expression.New platforms feature higher data quality, reduced costs per sample, and scalable systems, which collectively make large-scale RNA-Sequencing (RNA-Seq) projects more accessible and affordable for a broader range of researchers, including those in smaller academic labs and commercial enterprises. Continuous innovations, like patterned flow cell technology and semi-conductor sequencing, are accelerating the transition from older microarray technology to the more powerful, versatile, and high-resolution NGS-based transcriptomics.

• Rising Demand for Personalized Medicine

The accelerating move towards personalized medicine significantly boosts the global market for transcriptomics by emphasizing the need for individualized patient profiling. Transcriptomic analysis allows clinicians and researchers to understand the gene expression signature of a patient's cells, which is critical for identifying biomarkers that predict disease susceptibility, progression, and, most importantly, therapeutic response. This is particularly vital in oncology, where a tumor's specific RNA profile can predict if it will respond to a targeted drug or immunotherapy, maximizing patient benefit while minimizing the risks and costs of ineffective treatments. This predictive power is driving the adoption of transcriptomics in clinical settings and diagnostics.

Increasing Investments in Genomic Research

Significant and continuous investments from both the private and public sectors are acting as a major growth catalyst for the transcriptomics market. These funds are channeled into large-scale genomics projects, development of new sequencing platforms, and creation of vast genomic databases. For instance, Truveta's January 2025 investment of US$320 million for a massive public genomic database, aiming for 10 million genomic sequences, provides an unprecedented resource for transcriptomic studies. Additionally, strategic investments from industry giants like Illumina and Regeneron Pharmaceuticals are focused on drug discovery, validating new genetic targets, and integrating genomic data with AI-driven risk models to enhance precision patient care.

Key Trends in the Transcriptomics Market

• Integration of Transcriptomics with ML and AI

Machine learning (ML) and Artificial Intelligence (AI) are transforming transcriptomics data analysis by providing the computational power necessary to interpret the massive, complex datasets generated by modern sequencing. AI tools help in identifying subtle, complex relationships and gene expression patterns that would be invisible to traditional statistical methods. A pioneering example is the University of Toronto's scGPT (single-cell generative pre-trained transformer) model, published in February 2024, which uses deep learning to accurately predict the effects of genetic manipulation and seamlessly integrate data from multiple experimental batches. This integration significantly automates the discovery of novel biomarkers, accelerates drug target identification, and provides deeper, more meaningful insights into disease mechanisms like tumor microenvironment analysis.

• Advancements in Single-Cell Transcriptomics

The development of single-cell transcriptomics (scRNA-seq) has arguably been the most revolutionary technical advancement, moving the field beyond analyzing the average expression of thousands of cells (bulk sequencing) to studying the gene expression profile of individual cells. This high resolution is critical for tackling challenges posed by cellular heterogeneity, especially in complex tissues like tumors and the brain, where rare cell populations (like cancer stem cells or specific immune cell types) drive disease or drug resistance. Single-cell analysis allows for precise identification of novel and actionable therapeutic targets that are often masked in bulk samples, enabling researchers to map developmental trajectories and uncover detailed cell-cell communication networks with unprecedented accuracy.

• Increasing Application in Personalized Medicine

The clinical utility of transcriptomics is rapidly expanding, with an increasing number of clinical trials and diagnostic workflows incorporating it into personalized medicine strategies. By profiling an individual patient's transcriptome, healthcare providers can move beyond genetic predisposition to directly observe the active molecular state of the disease, which is influenced by both genetics and environment.

Leading Companies Operating in the Global Transcriptomics Industry:

• Agilent Technologies Inc.
• Becton Dickinson and Company
• BGI Group
• Bio-Rad Laboratories Inc.
• Biospyder Technologies Inc.
• Illumina Inc.
• Nanostring Technologies Inc.
• Qiagen
• Roche Holding AG
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

Transcriptomics Market Report Segmentation:

Breakup by Type:

• Instruments
• Consumables
• Software
• Services

Consumables represent the leading segment in the transcriptomics market with 43.8% shares, driven by their essential role in every phase of transcriptomic research.

Breakup by Technology:

• Microarray
• Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
• Sequencing Technologies

Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) is a leading technology segment in the transcriptomics market due to its unparalleled sensitivity, specificity, and quantification capabilities in gene expression analysis.

Breakup by Application:

• Diagnostics and Disease Profiling
• Drug Discovery
• Others

Drug discovery is a leading application segment, accounting for 33.8% of the market shares, driven by the growing need for precision medicine and innovative therapeutics.

Breakup by End User:

• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Others

Academic and research institutes drive the transcriptomics market through extensive basic and applied research on gene expression.

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the market with 37.7% of the market share due to its advanced healthcare infrastructure, strong focus on R&D, and robust funding from the public and private sectors.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302

by Yash mishra on 2025-12-17 01:18:53